Oncopeptides AB (publ)
ONPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.1% | 321.5% | -92.9% | – |
| Cost of Goods Sold | $0 | -$0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.6% | 103.1% | 99.9% | 55.1% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | -895.8% | -719.6% | -4,181.3% | -1,201.2% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | -899.3% | -707.3% | -4,044.9% | -1,209.1% |
| EPS | -1.87 | -2.76 | -4.11 | -19 |
| % Growth | 32.2% | 32.8% | 78.4% | – |
| EPS Diluted | -1.87 | -2.76 | -4.11 | -19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$1 |
| % Margin | -895.8% | -657.6% | -3,825.7% | -1,188.1% |